Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: August 2020

8/27/2020 Ranking of Russian Pharmacy Chains (Q1 – Q2 2020)

The acute phase of the COVID-19 epidemic in Russia has more or less passed, to the point that the coronavirus realities have even begun to be safely forgotten. The virus obviously has affected the pharmaceutical market in general and the pharmaceutical retail in particular, especially since there are enough “concomitant diseases” in the industry as it is. The results of the second quarter of 2020 are negative, as expected, the consumers have to settle for the stocks made during the rush, and the macroeconomics also leaves much to be desired.

8/19/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): 1 in 5 Russian Doctors Ready for COVID-19 Vaccination after Industrial Production Is Launched

19% of doctors say that they will definitely get vaccinated against coronavirus after such an opportunity arises, according to a survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Interestingly, a significant part of those who chose to write their own answer (4%) said they refuse to vaccinate due to a previous illness.

8/17/2020 Ranking of Russian Pharmaceutical Distributors (Q1 – Q2 2020)

The COVID-19 epidemic naturally became the central issue of the first half of the year. For distributors, it was a time of emergency work, a major change in both business processes and cooperation with the retail. Larger companies have long been trying to tighten relations with the retail, but the epidemic revived this trend, and made it one of the key issues in relations with partners. As a result, most of the top distributors have cut a considerable number of their delivery points. The top distributors’ share was also declining, but the factor of uneven market development was of prime importance here, since the state segment grew several times faster than the retail.

8/14/2020 Veterinary Vaccine Import to Russia (June and First Half of 2020)

Between January and June 2020, Russia imported 6.29 bln RUB worth of veterinary vaccines (customs clearance included), which is in monetary terms (rubles) 13% higher than in 2019, even though the importers stocked up their warehouses in late 2019. The import volume of veterinary vaccines in 2019 has grown by more than 37%. In the first half of 2020, the import volume amounted to 3.39 mln units, with the dynamics of +0.4%. If calculated in dosages, the dynamics are -6.7%, and the import volume is 23.32 bln dosages.

8/8/2020 Pharmaceutical Drug Production in Russia (First Half of 2020)

Between January and June 2020, Russia manufactured 232 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 24% higher than in 2019. The dynamics in physical terms (units) are +18.3%, with the manufacture volume of 2.45 bln units. If calculated in minimum dosage units (MDU), Russia manufactured 42.7 bln MDUs, with the dynamics of +21.2%.

8/7/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): Only 11% of Russian Doctors Agree with the Official Statistics Showing Decreased Rates of COVID-19 Incidence

44% of Russian doctors believe that the COVID-19 situation is stable, but at the same time note that the morbidity rates have not significantly reduced, according to a survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. This opinion is shared by 60% of the respondents residing in Moscow and St. Petersburg and by only 37% of those residing in the other regions. However, no one expects complete unanimity, because the epidemiological situation obviously differs from region to region.